VERONA PHARMA PLC

Analyst Reco. Verona Pharma plc

Equities

VRNA

US9250501064

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
15.47 ^USD	+1.05%		-1.59%	-22.18%

04-22	European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	MT
04-16	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Raises Verona Pharma's Price Target to $36 From $31, Keeps Overweight Rating	04-16	MT
Wedbush Raises Verona Pharma Price Target to $33 From $30, Maintains Outperform Rating	13/09/23	MT
Truist Securities Adjusts Price Target on Verona Pharma to $32 From $28, Maintains Buy Rating	07/06/23	MT
Possibility of US Fed's Rate Hike Pause Supports American Depositary Receipts of European Equities	23/03/23	MT
BTIG Adjusts Price Target on Verona Pharma to $31 From $26, Maintains Buy Rating	20/03/23	MT
European Equities Move Lower Following ECB Rate Hike	02/02/23	MT
HC Wainwright Adjusts Verona Pharma's Price Target to $32 From $30, Keeps Buy Rating	21/12/22	MT
Wedbush Raises Verona Pharma's Price Target to $30 From $23, Maintains Outperform Rating	20/12/22	MT
Truist Securities Adjusts Price Target on Verona Pharma to $28 From $20, Maintains Buy Rating	20/12/22	MT
BTIG Boosts Price Target on Verona Pharma to $26 From $17, Reiterates Buy Rating	20/12/22	MT
ECB, Bank of England Interest Rate Hikes Weigh Down European Equities	15/12/22	MT
Wedbush Lowers Verona Pharma's Price Target to $23 From $27 Due to Increased Share Count, Keeps Outperform Rating	10/11/22	MT
Wedbush Analyst Assumes Coverage on Verona Pharma at Outperform With $27 Price Target, Up From $23	19/09/22	MT
HC Wainwright Adjusts Verona Pharma's Price Target to $30 From $25, Reiterates Buy Rating	29/08/22	MT
Piper Sandler Initiates Coverage on Verona Pharma With Overweight Rating, $31 Price Target	26/08/22	MT
Wedbush Raises Verona Pharma's Price Target to $23 From $18, Maintains Outperform Rating	09/08/22	MT
Wedbush Cuts Verona Pharma's Price Target to $18 From $25, Adjusting Ensifentrine Launch Estimates; Outperform Rating Kept	17/06/22	MT
Canaccord Genuity Adjusts Price Target on Verona Pharma to $23 From $18, Keeps Buy Rating	12/11/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer